FDA approves Gen-Probe's Procleix Ultrio for HBV
This article was originally published in Clinica
Gen-Probe's Procleix Ultrio assay has been approved by the US FDA for an additional indication: screening donated blood for the hepatitis-B virus (HBV). The FDA approved the firm's supplemental biologics licence application (sBLA): these usually apply to drug approvals, but Gen-Probe explained that blood is treated as a drug by the FDA. Procleix Ultrio was first approved in October 2006 to screen blood and tissue for HIV-1 and the hepatitis-C virus (see Clinica No 1227, p 15), but the initial study did not demonstrate HBV yield. The San Diego, California-based firm then carried out postmarketing studies looking at HBV yield, with its partner Chiron, and filed the sBLA in February.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.